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ObesityGenome wide association studies undoubtedly linked variants of the fat mass and obesity-associated protein
(FTO) to obesity. To date, however, knowledge on the mechanisms coupling variants in the intron of the FTO
gene to its expression or enzymatic activity to alter metabolism remains scarce. Until recently, the investigation
of themolecular function of FTO had not led to conclusive results concerning the ‘where’, ‘when’ and ‘how’ of FTO
activity. Finally, since FTO was identiﬁed as a RNA modifying enzyme, demethylating N6-methyladenosine on
single stranded RNA, novel understanding of the molecular function is gathered. These and other studies suggest
the requirement for a further reaching approach to further investigate FTO function, since the phenotype of
aberrant FTO function may encompass more than just obesity. Taking these new insights and translating them
into appropriate paradigms for functional research in humans may lead to a deeper understanding of the
human physiology and disease. This article is part of a Special Issue entitled: From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Worldwide 1.4 billion people are overweight with approximately
one third of those considered obese (source: WHO). While some years
ago this was only regarded as a problem for developed countries,
recently the same trend is observed in developing countries [1]. Comor-
bidities such as type 2 diabetes, cardiovascular diseases and increased
risk for certain types of cancer not only decrease the individual's quality
of life, but also add a substantial burden to our health and economic
systems [2,3]. Thus, obesity has become a substantial socio-economic
problemnourishing the need to deepen our understanding of the genet-
ics and complex regulatorymechanisms governing energy homeostasis.
Accordingly, most recently the FDA has classiﬁed obesity as a disease
entity.
In the past, several loss-of-function mutations were identiﬁed
whose carriers inevitably face obesity [4]. The allelic frequencies for
these rare genetic variations underlying obesity, however, have not
changed since the prevalence of obesity started its dramatic rise in the
middle of the 20th century [5]. Instead environmental factors such as
lack of physical activity and the facilitated access to highly palatable,
energy dense food have been identiﬁed as the culprit behind common
obesity [5]. Although every member of a deﬁned population is exposed
to comparable environmental factors, considerable variation in the
individual body mass index is observed. Clearly, common obesity isnome to Function.
ights reserved.not caused by rare and fatal loss of function mutations, but rather
through the complex interplay of environmental factors and each
individual's susceptibility to these factors.
In recent years, many common genetic variations in the human
genome were identiﬁed in various ethnicities [6,7]. These allelic
polymorphisms, considering their individual effects, have only a minor
impact on body weight [6]. Through the sum of their effects, being
beneﬁcial or disadvantageous, these variations, however, deﬁne an
individual's predisposition to gain weight and present the framework
for polygenic obesity particularly in face of environmental changes.
Identiﬁcation of these subtle factors predisposing for obesity, can only
be the ﬁrst step in understanding the apparent variation in a given pop-
ulation. To decipher the underlying mechanisms of polygenic obesity, a
deep understanding of each associated gene with regards to its expres-
sion, molecular function, downstream pathways and interactions is
mandatory toﬁnally identify the alterations caused by one or fewnucle-
otide polymorphisms. In their entirety, all polymorphisms carried by an
organism present a complex network to investigate. While one gene
may play a crucial role in the homeostatic regulation of energy balance,
another one may impinge on hedonic aspects of food intake. As the
organism is, partly consciously, exposed to a whole plethora of environ-
mental input, even top down factors, such as cortical feedback
overruling the homeostatic system, have to be taken into account.
The aim of this review is to summarize research on the fat mass and
obesity-associated gene (FTO). In our view FTO represents a prime ex-
ample for the problems we are facing when trying to link polymor-
phisms and their associations to molecular function and molecular
function to established clinical associations.
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Fig. 1. Schematic summary of FTO research highlights. In humans, FTO genetic variation associates with increased BMI and inversely correlates with ADHD andmajor depression disorder
[8–10,13,23,43,45,46]. Themain reasons for the increase in bodyweight are an increased energy intake [16–20], impaired satiety response [22,25] and increased food responsiveness [23].
Loss of FTO in humans leads to a severe phenotype characterized by growth retardation and severe CNS defects [54]. On the molecular level, FTO was identiﬁed as a 2-oxoglutarate
dependent demethylase whose main substrates are m6A and m3U (crystal structure depicted in scheme adapted from [68]) [42,60,70]. Furthermore, FTO was found to be involved in
amino acid sensing [64,66], mTORC1 [66] regulation and leptin receptor clustering [32]. In mice, FTO is able to demethylate m6A in vivo and affects a speciﬁc subset of m6A modiﬁed
mRNAs [60,71,75,76]. Whole body FTO deﬁciency causes postnatal growth retardation, a lean phenotype and increased energy expenditure [65,78]. Moreover, browning of white adipo-
cytes was observed in FTO-deﬁcient mice [83]. In contrast, adult onset of FTO causes loss of leanmass through increased protein utilization [78]. Global overexpression, causes obesity due
to an increased food intake [63]. Virusmediatedmanipulation of FTO expression in the hypothalamus (HT)was demonstrated to inﬂuence food intake, however, studies so far have not led
to conclusive results [57,78]. DA neuron speciﬁc deletion of FTO on the other hand does not inﬂuence food intake or energy expenditure, but causes aberrant D2 autoreceptor function in
dopaminergic neurons [76]. Finally,ﬁrst functional studies inhumans demonstrated altered neuronal activity in response to food cues inhomeostatic, aswell as hedonic brain areas [25]. In
the future, hypotheses gathered in rodentmodelsmay lead theway for paradigms in human studies. Furthermore, these hypothesesmay allow the selection of other genes for a combined
gene-gene interaction analysis with FTO genotypes.
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2.1. FTO and obesity
FTO is one of the genes known to contribute to polygenic obesity. In
fact it was the ﬁrst one to be identiﬁed by genome wide association
studies (GWAS) [8–10] (see Fig. 1). While initially investigated as one
of the genes deleted in the fused toes (Ft)mousemutant [11,12], general
interest was triggered by its robust association with obesity in numer-
ous independent populations [8–10]. A cluster of single nucleotide poly-
morphism (SNPs) in the ﬁrst intron of the FTO gene was found to
correlate with an increase in body mass index (BMI) in both children
and adults, regardless of gender. Since these initial ﬁndings in 2007, the
association was repeatedly conﬁrmed in multiple cohorts spanning mul-
tiple ethnicities (see [13] for a comprehensive review). The overall effect
size for carriers of the FTO ‘risk-allele’ is, however, relatively small. Eachcopy of the ‘risk-allele’ accounts statistically for an increase in BMI
of ~0.4 kg/m2 [10]. While this association holds true for children older
than 5.5 years, adults and elderly [8–10,13–15], a META study identiﬁed
an inverse association of the rs9939609 ‘A’ allele for infants younger
than 2.5 years [14]. Additionally, each copy of the ‘A’ allele accelerated de-
velopment by 2.4%, resulting in earlier adiposity rebound [14].
Further studies narrowed the cause of increased BMI down to an
increase in energy intake [16–20], with evidence for a shift toward an
elevated fat consumption [19,21]. Moreover, children at the age of
4–5 years carrying the obesity ‘risk-allele’ are reported to have an
increased consumption of highly palatable food [20]. At this age the rever-
sal of FTO variant associationwith BMI is observed, thus leading to the as-
sumption that this behavior represents the underlying reason for the
increased BMI later in life. Consistently, several studies show an impaired
satiety response (age 8–11 years; questionnaire example: “My child can-
not eat a meal if he/she has had a snack just before.” (adapted from
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creased food responsiveness (age 3–4 years; questionnaire example:
“Even if my child is full, he/she ﬁnds room to eat his/her favorite food”
(adapted from Velders et al.)) [23] and lower postprandial responses in
hunger and satiety (31 ± 14 years) [24,25] (see Fig. 1).
Associations of FTO ‘risk-alleles’ with changes in physical activity/
energy expenditure are so far controversial. Physical inactivity [15],
increased physical activity [26] and failure to ﬁnd any association
[17,18,27–29] are reported. Vice versa, however, physical activity is
able to reduce the effect of FTO variants on BMI [30].
Taken together, genome wide association studies succeeded in
identifying variants in the FTO gene that signiﬁcantly correlate with an
increase in BMI irrespective of age or gender in multiple, though not
all, ethnicities. The most compelling evidence so far suggests increased
energy intake, probably through a preference for palatable food and
malfunctional eating responses, as the underlying reason for the
increase in BMI.
2.2. Functional aspects of single nucleotide polymorphisms
So far the functional outcome of FTO genotypes remains largely
unknown.Neither the exact consequences of the single nucleotide poly-
morphisms within the ﬁrst intron of the FTO gene are known, nor
whether these variations affect FTO expression at all. The ﬁrst intron of
the FTO gene might represent an important regulatory site for both
FTO, as well as RPGRIP1L (retinitis pigmentosa GTPase regulator-
interacting protein-1 like), whose transcriptional start is located in the
opposite direction of and close to the ﬁrst exon of FTO [31]. Evidence
points to a transcriptional co-regulation of both FTO and RPGRIP1L
through at least two putative CUX1 (also known as CUTL1) binding
sites within the SNP region of the ﬁrst FTO intron [31,32].When binding
to the obesity-associated region harboring one of these binding sites,
isoform P110 of CUX1 increases the promoter activity of FTO and
RPGRIP1L, while isoform P200 decreases the activity [32]. By increasing
the expression of FTO and RPGRIP1L, CUX1 potentially leads to an in-
creased leptin sensitivity through increasing leptin receptor clustering
at the ciliary pole of a neuron (experimental evidence in rodents) and
may ultimately decrease food intake [32]. Interestingly, one of the
obesity-associated SNPs (rs8050136), which is in close linkage disequi-
librium with the other SNPs in that region, exhibits a decreased p110
binding afﬁnity, thus resulting in decreased FTO and RPGRIP1L expres-
sion, potentially decreasing leptin sensitivity and thus may ﬁnally lead
to an increase in energy intake [31,32].
While the role for FTO in the proposed model of leptin receptor
clustering is not known, RPGRIP1L is part of the basal body of the cilium
and may represent an important player in clustering of signaling com-
ponents to the ciliary pole [33,34]. With respect to ‘ciliopathies’ and
obesity-associated loss of cilia in both men and mice, these ﬁndings
are of great interest [35–39]. Loss-of-function mutations of RPGRIP1L,
however, lead to the Joubert and Meckel syndromes, both of which
are associated with severe brain and renal abnormalities, but not obesi-
ty [40]. Correspondingly, Ftm knockout in mice (the ortholog of
RPGRIP1L) causes cerebral, renal and hepatic defects [34]. The proposed
connection of reduced FTO/RPGRIP1L expression and reduced leptin
sensitivity is thus contradictory to the non-obesity related loss of
RPGRIP1L in mice and men. However, the complexity and apparent
developmental defects in those loss-of-function models make a ﬁnal
conclusion difﬁcult and cannot rule out an important co-regulatory
role for both FTO and RPGRIP1L with respect to energy homeostasis.
2.3. More than just obesity?
Most of theGWA studies so far have addressed the correlation of FTO
genotype with obesity. In recent years, however, the repertoire of SNP
associations was extended to non-obesity related (at least not directly
related) behaviors. Carriers of the rs9939609 risk-allele, independentof the effect on BMI, appear to drink larger amounts of alcohol (beer
and spirits) at a given occasion, however, choose to do so less frequently
than non-carriers [41]. Overall, carriers have a reduced ethanol con-
sumption and correspondingly the risk-allele is inversely correlated
with alcohol dependency [41]. When questioned for their smoking
habits, homozygous carriers of rs9939609 turned out to smoke less
cigarettes per day in times of heavy smoking and started smoking
later in life [41].
Prompted by the high expression of FTO in the brain [42] and the
association of FTO variants with changes in eating behavior already at
young age [16,19–22], two independent research groups investigated,
whether FTO is linked to child behavior phenotypes. They successfully
linked rs9939609 [23] and rs8050136 [43] to attention-deﬁcit/
hyperactivity syndrome (ADHD), however, although unmedicated
ADHD is associated with an increased risk to develop childhood
overweight [44], the obesity ‘risk-alleles’ rs9939609 and rs8050136
are inversely correlated with ADHD independent of BMI [23,43] (see
Fig. 1). Moreover, children with the rs9939609 risk-allele have a better
emotional control and increased food responsiveness independent of
ADHD symptoms [23], of which the latter is in perfect agreement with
previous results demonstrating an impaired satiety responsiveness [22].
Continuing the list of psychiatric disorders, FTO variants are associated
with major depressive disorder. Depression was found to modify the
effect of several SNPs on BMI [45]. A subsequent study demonstrated
an inverse relationship between rs9939609 and depression, suggesting
a protective effect of the obesity risk-allele on depression [46] (see
Fig. 1). Each copy of the obesity associated ‘A’ allele was associated
with an8% reduction in depression risk, independent of age, sex, ethnic-
ity and BMI. Notably, depressionwas previously reported to be associat-
ed with an increased risk for obesity [47,48], while an inverse
association is reported for the obesity-associated FTO variant.
In addition to the associations with psychiatric disorders, FTO seems
to play a role in ageing-associated cognitive decline. Carrying one or two
copies of the rs9939609 ‘A’ allele correlates with a reduced verbal ﬂuen-
cy in obese elderly men, while normal weight carriers as well as normal
and overweight controls remain unaffected [49]. Conformingwith these
ﬁndings, the rs8050136 risk allele genotype correlates with worse per-
formance in measures of memory performance (California Verbal
Learning Test) in elderly subjects treated for cardiovascular disease
[50]. A third study conﬁrmed the correlation with cognitive decline,
independent of age, gender, diabetes and BMI [51].
Moreover, homozygous risk-allele carriers face a higher risk to
develop dementia and Alzheimer's disease [15]. While this association
is independent of differences in physical activity, BMI, diabetes and
cardiovascular disease, the FTO risk-allele is reported to interact with
the Alzheimer's apolipoprotein E (APOE) ε4 risk allele, almost triplicating
the risk for dementia and Alzheimer's [15].
In line with the aforementioned relationships, structural brain
changes are already observed in healthy elderly depending on FTO
genotype (SNP rs3751812) [52].
Finally, carriers of the obesity risk allele (rs9939609 ‘A’) were
reported to have an increased mortality rate, independent of obesity
[53]. Being homozygous for the non obesity-associated ‘T’ allele
corresponded with a 42% lower mortality. Notably, only amongst
carriers of the ‘A’ allele, diseases of the nervous system were found as
a cause of death. These cases, however, do not explain the overall
increased mortality of affected subjects [53].
2.4. Loss-of-function mutation
While the functional alterations of the single nucleotide polymor-
phisms in the intronic region of FTO still remain to be elucidated, rare
cases of loss-of-function mutations in the FTO gene demonstrate the
importance of a fully functional FTO protein for humans. Impaired
enzymatic function of FTO, due to a mutation of arginine 316 to gluta-
mine, causes postnatal growth retardation, microcephaly and brain
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facialmalformations and cardiac deﬁcits [54] (see Fig. 1). None of the re-
ported cases survived the autosomal recessive syndrome for more than
3 years. Moreover, cultured ﬁbroblasts of affected subjects showed im-
paired proliferation and accelerated senescence [54]. While the overall
symptoms are severe, some aspects, like structural brain changes and
cognitive deﬁcits are also observed for obesity-associated FTO variants
[49,52], again demonstrating the overall apparent importance of FTO
for the functional integrity of the central nervous system.
2.5. FTO trisomy
Few cases of partial trisomies of chromosome 16q, including the FTO
gene and leading to a copy number variation of FTO, are reported so far
[55,56]. Some of these patients share phenotypic features, which
include obesity, learning difﬁculties and behavioral problems such as
aggression and ADHD. However, it has to be pointed out that this repre-
sents not a clear association, as not all patients are e.g. obese [55]. The
nature of these chromosomal duplications, spanning large portions of
the proximal arm of chromosome 16 and including several annotated
genes, limit the conclusions drawn from these ﬁndings.
3. Molecular function
So far, the knowledge we gathered for this review relied mostly on
information collected from genome wide association studies. None of
these are, by nature of the method, able to predict any molecular
function for FTO and the pathways it may play a role in. In response to
the myriad of association studies, however, the combined efforts of
many groups helped in shedding light not only on the molecular
function, but also on the potential connection to metabolic syndrome
and energy homeostasis.
3.1. FTO expression
FTO is ubiquitously expressed [10,42]. Levels of FTO are, however,
relatively higher in the central nervous system, as compared to periph-
eral tissue [10,31,42,57,58]. Within the brain a strong expression was
reported for feeding related nuclei in the hypothalamus, namely the ar-
cuate, dorsomedial, ventromedial and paraventricular nuclei [42,57,59].
Within the cell, FTO primarily localizes to the nucleus [42,58] and par-
tially co-localizes with splicing factors in nuclear speckles, implicating
a role for FTO in mRNA splicing [60,61]. So far, however, there is no
evidence directly connecting FTO to mRNA processing.
The effect of the nutritional status on FTO expression is so far contro-
versial. 48 h fasting increased FTOmRNA in rats [59], while 48 h fasting
in mice [42] and long term food restriction in rats (60% ad libitum)
decreased transcript levels [62]. Other studies failed to observe any
changes in mice both after long time (40 h)[31] or overnight fasting
(18 h)[58]. On the protein level, overnight fasting had no inﬂuence
[58], while a reduction in FTO protein was observed in the hypothala-
mus and brainstem after long term food restriction in rats (60% of ad
libitum) [62]. Notably, the latter study demonstrated that the reduction
inmRNA and protein levels of FTO caused by caloric restriction depends
on leptin receptors and STAT3 signaling. Caloric restriction on a leptin
receptor deﬁcient background was not able to reduce FTO expres-
sion [62]. Moreover, in vivo centrally administered and in vitro bath
applied exogenous leptin is able to reduce hypothalamic FTO expres-
sion [62]. Conversely, reduced expression of FTO was proposed to play
a role in leptin receptor clustering and thus in control of leptin signaling
[32]. Overexpression of FTO in rat arcuate nucleus, on the other hand,
led to a 4-fold increase in mRNA levels of Stat3, a critical molecule in
leptin receptor signaling [57]. Furthermore FTO overexpression was
demonstrated to result in reduced fasting plasma leptin levels in 8
week old mice, but not at 20 weeks of age [63]. These results on
‘cause and effect’ of the relationship are contradictory, thus the apparentconnection of the potent regulator of energy intake leptin and FTO
demands further investigation.
3.2. FTO in amino acid sensing
In vitro glucose deprivation aswell as total amino acid deprivation of
hypothalamic cells (N46 cells) led to a reduction in both FTOmRNA and
protein levels [64]. Interestingly, essential amino acid deprivation
was sufﬁcient to reproduce this reduction, potentially pointing to the
pathway through which FTO is coupled to energy availability and
metabolism [64].
Both in vivo and in vitro FTO deﬁciency causes growth defects.
FTO-deﬁcient mice suffer from postnatal growth retardation [65].
MEFs derived from FTO-deﬁcient mice show slower growth rates
and reduced translation [66]. In vitro analysis demonstrated that
the multi-synthetase complex (MSC), that coordinates function of
aminoacyl-tRNA synthetases, is downregulated in FTO-deﬁcient MEFs.
Reintroducing FTO in these cells, however, rescued the MSC expression
and increased translation [66].Moreover,mTORC1, a critical regulator of
growth and translation, depends on the enzymatic activity of FTO [66]
(see Fig. 1). Downregulation of mTORC1, usually as a consequence of
amino acid deprivation, is prevented by reexpression of FTO [66]. How
FTO expression is regulated by amino acid availability and the mecha-
nism coupling demethylase activity of FTO toMSC andmTORC1 expres-
sion, however, demands further investigation.
3.3. FTO acting as a nucleic acid demethylase
Through bioinformatical sequence comparison, FTO was identiﬁed
as a homolog of Fe(II) and 2-oxoglutarate-dependent dioxygenases,
namely AlkB (Escherichia coli) and AlkB homologs (ABH1, ABH2 and
ABH3 in humans) [42,67,68]. Notably, FTO seems to be conserved in
vertebrates, as well as marine algae, but is absent in invertebrates
[42,59,67]. Within its sequence, the Fe(II) and 2-oxoglutarate (2-OG)
binding sites are conserved [42]. 2-Oxoglutarate (also known as
alpha-ketoglutarate) serves as a substrate for FTO and is an important
intermediate product of the Krebs-cycle (citric acid cycle). Following
formation through decarboxylation of oxalsuccinate, 2-OG is further
decarboxylated to succinyl-CoA. Assumptions that proposed 2-OG as
the link between FTO andmetabolism, however, appear to be less likely.
If FTOwas to be a sensor for 2-OG concentrations, its enzymatic activity
would need to depend on the physiological range of 2-OG concentra-
tions. The 2-OG Km for FTO, however, was found to be at 2.88 μM,
more than 10-fold below physiological concentrations of 2-OG [69],
leading to the conclusion that FTO is unlikely to be a sensor for 2OG
and to undergo physiologically relevant 2OG-dependent regulation.
In vitro FTO is able to demethylate 3-methylthymine in single stranded
DNA (ssDNA) and 3-methyluracil (m3U), as well as 6-methyl-adenosine
(m6A) in single stranded RNA (ssRNA) [42,60,61,70,71] (see Fig. 1). FTO
preferentially acts on ssDNA/RNA, rather then double-stranded [42,70],
a feature that is probably due to a novel C-terminal loop identiﬁed by
solving the crystal structure of FTO [68].Moreover, its efﬁciency is slightly
higher for RNA thanDNA, suggesting that ssRNA represents FTO's primary
target [61,70]. Whether m3U, m6A or even both modiﬁcations represent
the physiologically relevant substrate for FTO is yet to be ﬁnally
determined.
3.4. m6A demethylase and methylome
Quite surprisingly, FTOwasnot only theﬁrst gene identiﬁed through
genome wide association studies to contribute to polygenic obesity, it
was also the ﬁrst enzyme identiﬁed to reverse N6-methyl-adenosine
(m6A) RNA modiﬁcations [60]. Although this RNA modiﬁcation has
been known since the 1970s [72], until now the exact function of the
m6A mark on RNA remains to be elucidated. So far, m6A has been pro-
posed to play a role in mRNA splicing, nuclear export, stability and
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of epigenetic control of protein expression. Moreover, m6A modiﬁed
RNAs are not targeted by the innate immune system andmay represent
a mean of a cell to indentify endogenous from ‘foreign’ RNA [74].
Using transcriptome wide mapping of m6A sites, transcripts of over
7000 mammalian genes were found to undergo single to multiple
modiﬁcation [71,75]. Most of the m6A marks are located in the 3′UTR
of transcripts and near the stop codon. To a lesser extent, m6A sites
are detected in exons and 5′UTR of mRNAs and in long non-coding
RNAs. Importantly, the methylation pattern differs between tissues
and is partially altered in response to environmental changes in vitro
[71,75]. Recently, we were able to show that FTO acts in vivo as a m6A
demethylase [76] (see Fig. 1). Within the midbrain and striatal tissue
of FTO-deﬁcient mice we found 5000 hypermethylation peaks present
in ~1500 transcripts, when compared to control animals. By functional
annotation, these hypermethylated transcripts cluster within gene
ontologies related to neuronal signaling [76]. Hence, FTO does not
demethylate all known m6A modiﬁed mRNAs and seems to act on
tissue-speciﬁc and functionally distinct transcripts. Thus, depending
on the tissue, FTO may act on different m6A modiﬁed transcripts. Alter-
natively, different demethylases may act on speciﬁc sets of transcripts.
The recent identiﬁcation of a second demethylase, AlkBH5, further sup-
ports this idea [77]. While AlkBH5 like FTO demethylates m6Amodiﬁed
RNA, the expression proﬁle of AlkBH5 is opposing that of FTO. AlkBH5
ismainly expressed in the peripherywith little expression in the central
nervous system. Hence, FTO, AlkBH5 and other, yet unidentiﬁed
demethylases may orchestrate translation through tissue-speciﬁc and
environmentally triggered activity.
Further analysis of some candidate genes whose mRNAs exhibited
increased m6A-modiﬁcation in the absence of FTO in our study showed
that hypermethylated mRNAs have unchanged or even upregulated
mRNA expression, while they are downregulated on protein level,
supporting the previously suggested function for m6A in translational
regulation [76]. However, we were not able to detect this pattern for
all hypermethylated transcripts, suggestingmore complicated regulato-
ry mechanisms. In line with our results, overexpression of FTO in vitro
reduced m6A methylation of ghrelin mRNA [25]. Moreover, blood cells
of FTO homozygous ‘risk allele’ carriers (rs9939609 ‘AA’) were demon-
strated to have increased FTO expression accompanied by a reduction of
m6A modiﬁcation of ghrelin mRNA, increased ghrelin mRNA levels and
increased ghrelin protein levels [25].
4. Lessons from animal studies
4.1. Whole body FTO deﬁciency
Prompted by the GWA identiﬁcation, mouse models were used to
investigate in detail the physiological consequences of a loss of FTO.
Whole body Fto deletion in mice is characterized by a complex pheno-
type [65] (see Fig. 1). Due to an increase in energy expenditure and in-
creased systemic sympathetic activation and although they are less
active and relatively hyperphagic, FTO-deﬁcient mice exhibit a reduc-
tion in both lean and fat mass. Moreover, they suffer from postnatal
growth retardation and postnatal death (50% survival rate for homozy-
gous knockouts)[65]. These ﬁndings are in linewith the loss-of-function
mutation reported in humans [54]. FTO-deﬁcient mice, however, do not
reach the severity of the phenotype in FTO-deﬁcient humans. Interest-
ingly, heterozygousmice, while being generally healthier than their ho-
mozygous littermates, are protected from high fat diet induced weight
gain [65].
A recent study conﬁrmed these results for the global germline FTO
knockout and moreover investigated the effect of adult onset loss of
FTO in mice [78] (see Fig. 1). These mice overcome and thus eliminate
the effects of the postnatal growth retardation and reduced survival of
germline knockouts. Induction of global FTO-deﬁciency at the age of
6 weeks caused a weight reduction already 3 weeks later. This initialweight loss was mainly due to a reduction in lean mass. However, dur-
ing the following weeks, mice regained weight through an increase in
fat mass[78]. While no differences in absolute food intake or energy ex-
penditure were detected, the adult onset FTO-deﬁcient mice show
increased protein utilization, which may be the underlying reason for
the observed loss of lean mass. Clearly, the contrast between germline
and induced adult FTO deﬁciency implicates a role of FTO during embry-
onic and/or perinatal development.
4.2. Global FTO overexpression
Human FTO gene variants are associated with increased body
weight, while global FTO deﬁciency in mice results in a lean phenotype.
Thus, the intronic human FTO variants could potentially lead to FTO
overexpression. Indeed, two studies showed that FTOmRNA is upregu-
lated in peripheral blood cells of homozygous rs9930609 ‘risk-allele’
carriers [25,79].
Global FTO overexpression in mice leads to obesity in a gene dosage
dependent manner [63] (see Fig. 1). The increase in body mass and fat
mass is detected both on a normal chow diet (NCD), as well as high
fat diet (HFD). Consistently with the reported increase in energy intake
in humans [16–20], whole body overexpression in mice led to an in-
crease in food intake, again both on NCD and HFD [63]. As no
genotype-related differences in energy expenditure and physical activ-
itywere observed, the increase in food intake is themost probable cause
for the observed body weight differences [63].
4.3. FTO in adipose tissue
While the expression proﬁle suggests an important role for FTO in
the central nervous system, peripheral tissuesmay not remain unaffect-
ed by changes in FTO activity or expression [10,31,42,57,58].
In human white adipose tissue (both subcutaneous and visceral)
FTO mRNA expression inversely correlates with BMI and age [80] and
is downregulated during adipocyte differentiation [81]. Moreover,
female carriers of the rs9939609 risk-allele had lower lypolytic activity
in vivo and in vitro [82]. Recently, this ﬁndingwas conﬁrmed in a shRNA
mediated knock down of FTO in cultured human adipocytes [83]. Even
more strikingly, this study demonstrated a 4-fold increase in UCP-1
expression with a concomitant increase in mitochondrial uncoupling
upon FTO knock down [83]. Consistently, a comparable upregulation
of UCP-1 was found in white adipose tissue of FTO-deﬁcient mice [83].
FTO-deﬁcient mice exhibit an increase in energy expenditure reminis-
cent of a UCP-1 upregulation in brown adipose tissue [65]. Thus, the
‘browning’ of white adipocytes may represent a plausible explanation
for the energy expenditure phenotype observed in these mice.
4.4. CNS and FTO
Highest expression for FTO is detected in the central nervous system,
speciﬁcally in feeding related nuclei of the hypothalamus [42,58]. Thus,
FTOmay play a critical role in the central nervous system and in control
of the well-known regulatory pathways of energy homeostasis [84].
Brain speciﬁc FTO deletion in mice resembles several aspects of a
whole body deletion [85]. Just as in FTO-deﬁcientmice, brain speciﬁc de-
letion leads to postnatal growth retardation, reduced size, decreased
body weight due to decreased lean mass and reduced IGF-1 serum
concentrations. Interpretations of these results, however, have to be
viewed cautiously, as the Nestin-Cre line used in this study was report-
ed to have a hypopituitarism phenotype that might explain several of
these ﬁndings [86].
Further insightwas generated through virusmediated, hypothalam-
ic knock down and overexpression of FTO in rats. FTO overexpression in
the arcuate nucleus of the hypothalamus led to a decrease, while knock
down resulted in an increase in daily food intake [57]. Conversely,
knockout of FTO in the mediobasal hypothalamus in mice resulted in a
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just the arcuate nucleus, suggesting that depending on where FTO ex-
pression is altered, the outcome may vary.
Recently, we reported a role for FTO in controlling the activity of the
dopaminergic circuitry. While FTO-deﬁcient mice fail to show any
response to the locomotor stimulatory effects of cocaine, dopamine
neuron restricted knockout of FTO led to cocaine hypersensitivity [76].
We were further able to demonstrate that the D2/D3-receptor depen-
dent autoinhibition of dopaminergic neurons is affected by loss of FTO.
Despite these changes, dopamine neuron restricted knockout mice
did not show any alterations in body weight, food intake or energy
expenditure [76]. Most probably, everyday life is not affected by the
attenuation of autoinhibitory function and may be compensated on
the network level. It is only as the system is pushed to its limits by
means of cocaine that subtle malfunctions can be detected. This conclu-
sion is consistent with the lack of an energy homeostasis phenotype in
mice lacking D2 autoreceptors in dopaminergic neurons [87]. Although
no alterations in energy intake were observed, our ﬁndings raise the
possibility that the dopaminergic circuitry is postsynaptically affected
in human ‘risk-allele’ carriers.
Malfunctions of the dopaminergic reward circuitry are long
established to impact hedonic aspects of food intake [88]. Impaired
satiety response, loss of control over eating and increased food respon-
siveness observed in human ‘risk-allele’ carriers, imply to some extent a
malfunction of the hedonic control of eating behavior. Moreover, the
obesity ‘risk-allele’ is associated with psychological disorders such as
depression and alcohol dependence, which have been previously linked
to dopaminergic function [89]. Thus, further studies need to address not
only the integrity of the neuronal circuitry underlying hedonic control
of eating behavior, but should also broaden the scope of investigation
for FTO single nucleotide polymorphisms to non-obesity related
diseases.
First evidence for alterations of human brain function, including the
dopaminergic reward circuitry, stem from a recent study investigating
the orexigenic hormone ghrelin with respect to FTO genotypes [25]. In
both fed and fasted state, FTO-deﬁcient mice exhibit a decreased acyl-
ghrelin/total ghrelin ratio. Overexpression of FTO in vitro on the other
hand increased the acyl-ghrelin/total ghrelin ratio, a result that was
also found postprandially in rs9939609 homozygous ‘risk-allele’
carriers[25]. Acyl-ghrelin, generated by posttranslational modiﬁcation
of ghrelin, is known to stimulate hunger and increase food intake [90].
Thus, failure to reduce acyl-ghrelin levels after food intake may account
for an increased energy intake in human ‘risk-allele’ carriers. Conﬁrming
earlier ﬁndings [24], FTO ‘risk-allele’ carriers showed attenuated
suppression of hunger following a standardized test-meal [25]. Most
strikingly, in both fed and fasted state, neuronal responses to food im-
ages were affected in subjects homozygous for the rs9939609 ‘A’ allele
(see Fig. 1). These alterations included brain regions associatedwith ho-
meostatic, as well as hedonic control of food intake. Furthermore, the
neuronal activity in response to highly palatable food images covaried
in appetite, reward and incentive motivation associated brain regions
positively with increasing acyl-ghrelin levels in controls, while it nega-
tively covaried in ‘risk-allele’ carriers [25]. Thus, these ﬁndings revealed
that the human FTO variants can be linked to functional alterations in
brain responsivity and link these ﬁndings to the orexigenic effects of
ghrelin.
5. Discussion
Clearly, by nature of the method, GWA studies can neither deliver
any insight into the biological function of the gene in question, nor if
the associated single nucleotide polymorphisms are functionally related
to the gene in question at all. Furthermore, if one does not want to rely
on serendipity, it is difﬁcult to assess human behavior with respect to
SNP variations, without preceding information on mechanism and tar-
get location of the gene under investigation. To address these questions,use of in vitro and in vivo models allows far more severe genetic
manipulations and ﬁnally overcome the limitations of GWA studies.
The large amount of genomewide association studies leave nodoubt
that FTO genotypes in humans are linked to obesity. But what do we
actually know about the underlying mechanisms that indisputably
connect FTO to energy homeostasis?
Compelling evidence deﬁned FTO as a 2-oxoglutarate dependent
demethylase, whose main substrate is N6-methyladenosine (m6A).
The functional outcome of this nucleoside modiﬁcation and whether
m6A is the only substrate of FTO, however, remains to be determined.
Nevertheless, its hypothesized role in regulating expression and
possibly acting on whole gene sets, render it an interesting candidate
in control of physiological networks, such as the homeostatic or hedonic
circuitry. Environmental changes, such as periods of starvation, may
alter the availability of essential amino acids and thus FTO expression.
The following changes in the tissue speciﬁc methylation pattern of
whole gene sets may subsequently change the properties of e.g. the ho-
meostatic or hedonic circuits, ﬁnally altering each individual's feeding
behavior in a complex manner. Through this mechanism, FTO could
reset the baseline responsiveness of the reward circuitry to external
stimuli and render the individual more susceptible to less rewarding
stimuli as compared to times of plenty. The ﬁndings of Karra et al.
already support the idea of changed responsiveness in different brain
areas of FTO ‘risk-allele’ carriers to external cues (in this case
food representations) including nuclei of the reward circuitry [25].
Moreover, we were able to show that conditional inactivation of FTO
in dopaminergic neurons alters responsiveness of the reward circuitry
in mice [76].
The major component of the human FTO phenotype seems to be
related to energy intake. More precisely, ‘risk-allele’ carriers exhibit
increased intake of highly palatable food and exhibit aberrant food
responsiveness and satiety [20,22,23]. The nature of the role of FTO
already seems to be complex and multidimensional, when it comes to
its primary phenotype. But could there be evidence linking the aberrant
behavior of the dopaminergic circuitry seen in both human fMRI [25], as
well as rodent experiments [76]?
The inverse associations of the obesity risk alleles with psychiatric
disorders such as addictive behavior, ADHD and depression are surpris-
ing, especially since ADHD and depression were previously associated
with increased body weight [91,92]. Velders et al. [23] propose in their
study a possible explanation for the inverse correlation with ADHD
that might as well serve as an explanation for the inverse associations
with alcohol dependency and major depressive disorder. Imbalances
in dopaminergic signaling are closely related to the psychiatric
disorders ADHD, addiction and depression [89]. Eating and especially
the enjoyment of food, on the other hand, impinge on the very same
pathway [93]. Hence, the observed overeating of highly palatable food
in ‘risk-allele’ carriers [20,21] may present a self-medication [23],
leading to an attenuation of the symptoms of ADHD, addiction and
depression.
Is FTO speciﬁcally affecting only one brain area or functional circuit?
Most likely not. The apparent tissue speciﬁc methylation pattern [71]
and selective, and tissue dependent action of FTO on subsets of the
whole methylome [76], are warranting the detailed investigation of
FTO action for a variety of circuits and cell populations. FTO expression
was reported for the whole central nervous system and especially in
the hypothalamic nuclei responsible for the homeostatic control of
feeding behavior [42,58]. Moreover, hypothalamic speciﬁc manipulation
delivered ﬁrst insights into FTO's role in the homeostatic circuitry
[57,78]. The results, however, are so far partly contradictory.
Comparison of germline and adult onset FTO knockout in rodents
may suggest yet another factor, that so far has not been taken into ac-
count. Adult onset deletion of FTO overcomes the growth retardation,
a developmental defect that manifests itself in germline FTO-deﬁcient
mice after birth. Growth, however, may not be the only affected devel-
opmental process. It is well established that during the lactation period
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important developmental processes take place in the central nervous
system. Circuits are wired or exhibit plasticity that may rewire already
established connections [94]. Hence, the developmental defects affect-
ing growth in germline FTO-deﬁcient mice may also impinge on the
development of e.g. homeostatic control circuits. As a consequence, it
may not only matter ‘where’, but also ‘when’ FTO expression is altered.
Therefore, further studies using both tissue speciﬁc germline, as well as
adult onset manipulations are needed to dissect developmental and
acute effects of changes in FTO expression.5.1. GWAS – rodents – round trip?
With the information gathered so far cause and effect are yet difﬁcult
to determine and further investigation is needed to unravel the appar-
ent pleiotropic nature of FTO action. The various evidence gathered
through rodent and cell culture experiments may prove vital in provid-
ing important hints as to where research should focus in humans.
Narrowing down the circuits and ﬁnally molecular targets relying on
FTO function in rodentmodelsmay deliver the framework for the devel-
opment of appropriatemeans, such as behavioral assessments and func-
tional MRI paradigms, for the investigation of human FTO genotypes
(see Fig. 1).
FTO has come a longway. After its identiﬁcation in genomewide as-
sociation studies only 6 years ago, we gathered a lot of information
through in vitro and in vivo studies potentially guiding our way back
to human physiology. Still the most important question remains, with
yet no promising approach to answer it: How would one gene, e.g.
FTO, ﬁt in the complex network of genotypic variation underlying
‘polygenic obesity’ and ﬁnally shaping the individual susceptibility to
obesity? Thus importantly, a better understanding of the function and
identity of circuits relying on FTO may aid in selecting other polygenic
risk factors putatively acting in a synergistic or opposing fashion to
FTO for a combined investigation.References
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